DNALite, now known as Particella, Inc., is a pioneering biotechnology company focused on creating a new category of medicines that address the limitations of current biological treatments. With a strong commitment to advancing healthcare, Particella utilizes its proprietary vector technology to develop oral gene medicines that are both repeatable and non-immunogenic. Particella's groundbreaking approach involves modifying the gastrointestinal (GI) tract to restore its functionality in patients with genetic diseases or compromised mucosa.

By harnessing their vector technology, the company delivers mRNA and other nucleic acids to GI cells, effectively combating intestinal and systemic diseases. With a focus on treating the root causes of GI diseases, Particella is revolutionizing the field of genetic medicine. Through their innovative research and development efforts, they aim to provide effective treatments for patients suffering from various conditions.

To learn more about the indications targeted by Particella or to get in touch with the company, visit their website or connect with them on LinkedIn and Twitter. Located in San Francisco, California, Particella is dedicated to pushing the boundaries of medicine and improving patient outcomes